Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1301 to 1310 of 1856 total matches.
Mumps Outbreak
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014 (Issue 1438)
and older
students at risk of exposure, vaccination consists of 2 doses
of MMR vaccine at least 28 days ...
An outbreak of mumps has occurred among students at
Fordham University in New York. All of those who developed
mumps had been vaccinated against the disease.
In Brief: Enteric-Coated Aspirin as an Antiplatelet Drug
The Medical Letter on Drugs and Therapeutics • Apr 28, 2014 (Issue 1441)
activation and aggregation for the life of the platelet
(5-7 days). Aspirin prophylaxis reduces ...
One of our readers has suggested that more attention should have been paid to a study comparing the antiplatelet effects of immediate-release and enteric-coated aspirin that appeared in Circulation last year.1 The safety benefits of enteric-coated aspirin are unclear. It may protect against dyspepsia, but not against major gastrointestinal bleeding, which is thought to be mainly a systemic effect of prostaglandin inhibition.ANTIPLATELET EFFECTS OF ASPIRIN — Aspirin irreversibly acetylates cyclooxygenase-1, blocking thromboxane synthesis and inhibiting platelet activation and aggregation for...
In Brief: Concerns about Oseltamivir (Tamiflu)
The Medical Letter on Drugs and Therapeutics • Jan 19, 2015 (Issue 1460)
shorten the duration of symptoms
by about one day. Most controlled trials of the
effectiveness ...
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk patients with confirmed or suspected influenza illness, citing the British Medical Journal and The Cochrane Collaboration, which have contended that there is no acceptable evidence that the drug prevents complications or hospitalizations and have questioned the completeness of the results of controlled trials conducted by the manufacturer (Roche).
In Brief: A New Formulation of Posaconazole (Noxafil)
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015 (Issue 1461)
vials. The recommended dosage is
300 mg administered intravenously over 90 minutes
twice on day 1 ...
The FDA has approved an IV formulation of the antifungal drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults at high risk for these infections, such as those with prolonged neutropenia. Posaconazole is also available as delayed-release tablets and an oral suspension.With activity against Aspergillus and Candida, posaconazole has an antifungal spectrum similar to that of voriconazole (Vfend, and generics), but unlike voriconazole it is also active against many species of Mucorales (formerly called Zygomycetes), such as Mucor and Rhizopus....
In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015 (Issue 1466)
2-12 days in 3 others. One patient died of cardiac arrest
and 3 required pacemaker implantation ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...
In Brief: Acalabrutinib (Calquence) for Mantle Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
comparing
acalabrutinib with ibrutinib are available to date.
The cost of 30 days’ treatment ...
The FDA has approved the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence – AstraZeneca) for oral treatment of relapsed or refractory mantle cell lymphoma. Acalabrutinib is the second BTK inhibitor to be approved for this indication; ibrutinib (Imbruvica) was approved in 2013.Ibrutinib inhibits other kinases in addition to BTK and has been associated with severe adverse effects, particularly atrial fibrillation, infection, rash, and bleeding, that may be related to inhibition of kinases other than BTK.1 Acalabrutinib is a more selective BTK inhibitor than ibrutinib; whether...
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
of
COVID-19 with onset ≥7 days after the second dose
among SARS-CoV-2-naive subjects who received ...
On May 10, 2021, the FDA expanded its Emergency
Use Authorization (EUA) for the Pfizer/BioNTech
mRNA-based COVID-19 vaccine to include adolescents
12-15 years old.1The vaccine has been
authorized for use in persons ≥16 years old since
December 2020.
In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
occurred within 42 days of vaccination; 95 of the 100
persons who developed GBS required hospitalization ...
On July 12, 2021, the FDA added a warning to the
Fact Sheet for the Johnson & Johnson (Janssen)
adenovirus-based COVID-19 vaccine about an
increased risk of Guillain-Barré syndrome (GBS)
following administration of the product.
In Brief: Merilog — A NovoLog Biosimilar
The Medical Letter on Drugs and Therapeutics • Mar 11, 2025 (Issue 5101)
negotiated rate for a 30-day supply
of NovoLog is $119.
1. SK Garg et al. Efficacy and safety of insulin ...
The FDA has approved Merilog (Sanofi), a biosimilar to
rapid-acting insulin aspart (NovoLog), for treatment of
patients with type 1 or type 2 diabetes. Merilog is the
first rapid-acting insulin biosimilar product to become
available in the US.
Med Lett Drugs Ther. 2025 Mar 11;67(5101):1 doi:10.58347/tml.2025.5101a | Show Introduction Hide Introduction
In Brief: A Home Test for Chlamydia, Gonorrhea, and Trichomoniasis
The Medical Letter on Drugs and Therapeutics • May 12, 2025 (Issue 1728)
about 3-5 days for
results to be delivered, which could delay treatment.1
Individuals who ...
The FDA has authorized use of the Visby Medical
Women's Sexual Health Test (Visby), an at-home
test available without a prescription, for detection of
Chlamydia trachomatis, Neisseria gonorrhoeae, and
Trichomonas vaginalis infections in women with and
without symptoms. It is the first test to become available
in the US for these sexually transmitted infections
(STIs) that can be performed entirely at home. Other
at-home tests are available in the US for diagnosis of
chlamydia, gonorrhea, and trichomoniaisis, but they
require mailing a urine or blood sample to a...
Med Lett Drugs Ther. 2025 May 12;67(1728):80 doi:10.58347/tml.2025.1728e | Show Introduction Hide Introduction